Escaping the “Valley of Death”— The Funding Process for Biotechnology Companies

Innovative biotechnology companies have the potential to transform healthcare, developing new therapies that may improve, as well as extend, the lives of patients. Delivering on this promise is an epic journey that may take one to two decades, unimaginable amounts of cash, and surviving the notorious valley of death. Read what Christopher J. Calhoun, Chairman & CEO of PARACRINE has to say.

Why Ceros Focuses on Funding Medical Technology Start-ups

Medical Device News Magazine spoke with CEO Mark Goldwasser about the potential of the medtech sector, companies that Ceros has funded so far, and what he sees ahead. 
- Advertisement -spot_img

Latest News

The Role of Impurity Checks in Your Medicine

Whenever you retrieve a prescription from a pharmacy, you're placing your trust in the medication's safety and efficacy. This...
- Advertisement -spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy